Medable Introduces New eCOA Platform to Streamline Clinical Trial Launches

Medable Inc., a technology platform provider specializing in clinical trials, has announced the launch of Medable Studio, an all-in-one application designed to streamline the configuration, translation, validation, and deployment of electronic Clinical Outcome Assessments (eCOA) within clinical trials. The new platform, now available, allows biopharmaceutical companies to expedite the traditionally time-consuming process of study startup, offering increased transparency and control.

Medable Studio is a no-code suite that simplifies the eCOA launch process. The platform offers users various options, including self-service, full-service, or hybrid approaches, all aimed at enhancing time and cost efficiency.

Medable asserts that its new platform can reduce the time required for configuring and translating study designs from months to hours. The user interface is designed to be intuitive, enabling non-technical users to quickly build and launch complex clinical trials.

Tim Smith, Medable's Chief Technology Officer and co-founder, commented on the platform's impact:

"Medable Studio upends the traditional study build/test/launch process by streamlining it using intelligence and automation. With Medable Studio, timelines shift from weeks and months to just days."

The platform includes several features:

• Point-and-Click Builder: Allows for rapid creation of assessments, instruments, and diaries with no-code formatting and live preview capabilities.
• Visual Schedule of Assessments Builder: Facilitates the configuration of standard and unscheduled visits, workflows, and notifications within the study schedule.
• Translation Workbench: A tool designed to manage translations more efficiently, reducing bottlenecks by enabling selective editing and importation.
• Content Library: Stores assessments, instruments, translations, and locales, allowing for easy reuse in future studies.

Michelle Longmire, CEO and co-founder of Medable, emphasized the broader implications of the platform:

"This is just the start to transforming how evidence is generated. Medable Studio is where trial teams go to create. It allows for greater scalability, efficiency gains, and better, protocol-fit science."

Medable Studio is part of Medable's broader software-as-a-service evidence generation platform, which includes eCOA+, Total Consent, Sensors, and Televisit. The platform has already been adopted by two top-10 pharmaceutical companies, demonstrating early traction in the industry.

Medable's platform has been deployed in over 300 decentralized and hybrid clinical trials across 60 countries, serving more than one million patients and research participants. According to a study by Tufts Center for the Study of Drug Development (CSDD), decentralized trials, such as those supported by Medable, can provide significant financial benefits, with potential returns ranging from five to 13 times the investment in Phase II and Phase III trials.

See also: 11 Notable Companies Enabling Decentralized Clinical Trials

For those interested in learning more about Medable Studio, a virtual live showcase is scheduled for August 27, 2024.

Topics: Clinical Trials